HepatologyNews.net

Hepatology Xagena

Epidemiological, genetic and clinical data presented at the International Liver Congress 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment ...


Low-dose oral Interferon could exert immune-modulating effects in human. Researchers have conducted a clinical trial to investigate the efficacy of oral Interferon-alpha in preventing hepatitis C rela ...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin has showed efficacy against the hepatitis C ...


A phase III study has enrolled 217 patients with primary biliary cirrhosis who had either failed to get an adequate response with UDCA ( Ursodeoxycholic acid ), or had been unable to tolerate it. Pa ...


Researchers have determined that sarcopenia, a loss of skeletal muscle mass, increases risk of sepsis and mortality risk in patients undergoing live donor liver transplantation. Findings published in ...


All-oral combination therapy is desirable for patients with chronic hepatitis C virus ( HCV ) infection. Researchers evaluated Daclatasvir ( an HCV NS5A replication complex inhibitor ) plus Sofosbuvir ...


The existence of a direct pathogenic link between hepatitis C virus ( HCV ) infection and myocardial injury has not been confirmed. Researchers have investigated the association between myocardial con ...


Whether long-term suppression of replication of hepatitis B virus ( HBV ) has any beneficial effect on regression of advanced liver fibrosis associated with chronic HBV infection remains unclear. A s ...


Rifaximin ( Normix, Xifaxan ) is a gut-selective, oral antimicrobial agent shown to reduce the recurrence of overt hepatic encephalopathy ( HE) and HE-related hospitalizations in a 6-month, randomized ...


The stability and propagation of hepatitis C virus ( HCV ) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 ( miR-122 ). Miravirsen is a locked nucleic ...


Patients chronically infected with hepatitis C virus ( HCV ) genotype 2 or 3 for whom treatment with Peginterferon is not an option, or who have not had a response to prior interferon treatment, curre ...


Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus ( HCV ) infection.In the phase 2b, randomized, open-label trial of Faldaprevir ( a proteas ...


There is a need for Interferon-free treatment regimens for hepatitis C virus ( HCV ) infection. The goal of a study was to evaluate ABT-450, a potent HCV NS3 protease inhibitor, combined with low-dose ...


The standard treatment for hepatitis C virus ( HCV ) infection is Interferon, which is administered subcutaneously and can have troublesome side effects.Researchers have evaluated Sofosbuvir ( Sovaldi ...


A study has evaluated the efficacy and safety of a new treatment regimen consisting of dose-dense Cisplatin-based chemotherapy and radical surgery in children with high-risk hepatoblastoma.SIOPEL-4 wa ...